Identification of human immunodeficiency virus -1 E protein-targeting lead compounds by pharmacophore based screening

References

1. 1.↵
   1. Baucom C,
   2. Bate J,
   3. Ochoa S,
   4. Santos I,
   5. Sergios A,
   6. Lorentzen L, et al.

   The epidemiology of the aids pandemic: historical, cultural, political, societal perspectives and knowledge of HIV. J Stud Res 2019; 8.
2. 2.↵
   1. Eisinger RW,
   2. Fauci AS.

   Ending the HIV/AIDS pandemic¹. Emerg Infect Dis 2018; 24: 413–416.

   OpenUrl
3. 3.↵
   1. Bruxelle J-F,
   2. Trattnig N,
   3. Mureithi MW,
   4. Landais E,
   5. Pantophlet R.

   HIV-1 entry and prospects for protecting against infection. Microorganisms 2021; 9: 228.

   OpenUrl
4. 4.↵
   1. Stockdale AJ,
   2. Saunders MJ,
   3. Boyd MA,
   4. Bonnett LJ,
   5. Johnston V,
   6. Wandeler G, et al.

   Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: A systematic review and meta-analysis. Clinical Infectious Diseases 2018; 66: 1846–1857.

   OpenUrl
5. 5.↵
   1. Chen GJ,
   2. Sun HY,
   3. Chang SY,
   4. Cheng A,
   5. Huang YS,
   6. Lin KY, et al.

   Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. Int J Antimicrob Agents 2019; 54: 35–42.

   OpenUrl
6. 6.↵
   1. Obasa AE,
   2. Mikasi SG,
   3. Brado D,
   4. Cloete R,
   5. Singh K,
   6. Neogi U, et al.

   Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa. Front Microbiol 2020; 11: 438.

   OpenUrl
7. 7.↵
   1. Chimukangara B,
   2. Lessells RJ,
   3. Sartorius B,
   4. Gounder L,
   5. Manyana S,
   6. Pillay M, et al.

   HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal province, South Africa. J Glob Antimicrob Resist 2022; 29: 468–475.

   OpenUrl
8. 8.↵
   1. de la Peña AT,
   2. Sanders RW.

   Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Retrovirology 2018; 15: 63.

   OpenUrlCrossRef
9. 9.↵
   1. Beitari S,
   2. Wang Y,
   3. Liu SL,
   4. Liang C.

   HIV-1 Envelope glycoprotein at the interface of host restriction and virus evasion. Viruses 2019; 11: 311.

   OpenUrlCrossRef
10. 10.↵
    1. Lu W,
    2. Chen S,
    3. Yu J,
    4. Behrens R,
    5. Wiggins J,
    6. Sherer N, et al.

    The polar region of the HIV-1 envelope protein determines viral fusion and infectivity by stabilizing the gp120-gp41 association. J Virol 2019; 93: e02128–e02218.

    OpenUrl
11. 11.↵
    1. Prévost J,
    2. Tolbert WD,
    3. Medjahed H,
    4. Sherburn RT,
    5. Madani N,
    6. Zoubchenok D, et al.

    The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site. mBio 2020; 11: e00280–e00320.

    OpenUrl
12. 12.↵
    1. Rullo EV,
    2. Ceccarelli M,
    3. Condorelli F,
    4. Facciolà A,
    5. Visalli G,
    6. D’Aleo F, et al.

    Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review). Mol Med Rep 2019; 19: 1987–1995.

    OpenUrl
13. 13.
    1. Allen AG,
    2. Chung C-H,
    3. Atkins A,
    4. Dampier W,
    5. Khalili K,
    6. Nonnemacher MR, et al.

    Gene editing of HIV-1 co-receptors to prevent and/or cure virus infection. Front Microbiol 2018; 9.
14. 14.
    1. Smith LK,
    2. Babcock IW,
    3. Minamide LS,
    4. Shaw AE,
    5. Bamburg JR,
    6. Kuhn TB.

    Direct interaction of HIV gp120 with neuronal CXCR4 and CCR5 receptors induces cofilin-actin rod pathology via a cellular prion protein- and NOX-dependent mechanism. PLoS One 2021; 16: e0248309.

    OpenUrl
15. 15.
    1. Smith LK,
    2. Kuhn TB,
    3. Chen J,
    4. Bamburg JR.

    HIV associated neurodegenerative disorders: a new perspective on the role of lipid rafts in gp120-mediated neurotoxicity. Current HIV Research 2018; 16: 258–269.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Nickoloff-Bybel EA,
    2. Festa L,
    3. Meucci O,
    4. Gaskill PJ.

    Co-receptor signaling in the pathogenesis of neuroHIV. Retrovirology 2021; 18: 24.

    OpenUrl
17. 17.↵
    1. Lahiry P,
    2. Torkamani A,
    3. Schork NJ,
    4. Hegele RA.

    Kinase mutations in human disease: interpreting genotype–phenotype relationships. Nat Rev Genet 2010; 11: 60–74.

    OpenUrlCrossRefPubMed
18. 18.
    1. Lai YT.

    Small Molecule HIV-1 Attachment inhibitors: discovery, mode of action and structural basis of inhibition. Viruses 2021; 13: 843.

    OpenUrl
19. 19.
    1. Meuser ME,
    2. Murphy MB,
    3. Rashad AA,
    4. Cocklin S.

    Kinetic characterization of novel HIV-1 entry inhibitors: discovery of a relationship between off-rate and potency. Molecules 2018; 23: 1940.

    OpenUrl
20. 20.
    1. Zhao C,
    2. Princiotto A,
    3. Farrell M

    , Smith III AB, Madani N, Sodroski J. Investigating the mechanism of a unique human immunodeficiency virus-1 (HIV-1) entry inhibitor, MF275. Open Forum Infect Dis 2018; 5: S200–S201.

    OpenUrl
21. 21.
    1. Hosny A,
    2. Ashton M,
    3. Gong Y,
    4. McGarry K.

    The development of a predictive model to identify potential HIV-1 attachment inhibitors. Comput Biol Med 2020; 120: 103743.

    OpenUrl
22. 22.
    1. Mostashari Rad T,
    2. Saghaie L,
    3. Fassihi A.

    HIV-1 entry inhibitors: a review of experimental and computational studies. Chem Biodivers 2018; 15: e1800159.

    OpenUrl
23. 23.
    1. Rodríguez-Izquierdo I,
    2. Natalia C,
    3. García F

    , los Ángeles Muñoz-Fernandez M de. G2-S16 sulfonate dendrimer as new therapy for treatment failure in HIV-1 entry inhibitors. Nanomedicine 2019; 14: 1095–1107.

    OpenUrl
24. 24.
    1. Yin S,
    2. Zhang X,
    3. Lai F,
    4. Liang T,
    5. Wen J,
    6. Lin W et al.

    Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope. FEBS Lett 2018; 592: 2361–2377.

    OpenUrl
25. 25.↵
    1. Curreli F,
    2. Belov DS,
    3. Kwon YD,
    4. Ramesh R,
    5. Furimsky AM,
    6. O’Loughlin K et al.

    Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120. Eur J Med Chem 2018; 154: 367–391.

    OpenUrl
26. 26.↵
    1. Wang T,
    2. Ueda Y,
    3. Zhang Z,
    4. Yin Z,
    5. Matiskella J,
    6. Pearce BC,et al.

    Discovery of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir. J Med Chem 2018; 61: 6308–6327.

    OpenUrl
27. 27.↵
    1. Liu J,
    2. Bartesaghi A,
    3. Borgnia MJ,
    4. Sapiro G,
    5. Subramaniam S.

    Molecular architecture of native HIV-1 gp120 trimers. Nature 2008; 455: 109–113.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Sabe VT,
    2. Ntombela T,
    3. Jhamba LA,
    4. Maguire GEM,
    5. Govender T,
    6. Naicker T, et al.

    Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. Eur J Med Chem 2021; 224: 113705.

    OpenUrl
29. 29.
    1. da Silva Rocha SFL,
    2. Olanda CG,
    3. Fokoue HH

    , Sant’Anna CMR. Virtual screening techniques in drug discovery: review and recent applications. Curr Top Med Chem 2019; 19: 1751–1767.

    OpenUrl
30. 30.↵
    1. Török B,
    2. Dransfield T

    1. Török M

    1. Williams JC,
    2. Opare S,
    3. Sugadoss SK,
    4. Ganesan A,
    5. Kalyaanamoorthy S.

    Chapter 5 - Virtual screening techniques in pharmaceutical research. In: Török B, Dransfield T, Török M (eds). Contemporary Chemical Approaches for Green and Sustainable Drugs. Elsevier; (Amsterdam) Netherlands: 2022. pp 89–128.
31. 31.↵
    1. Karami TK,
    2. Hailu S,
    3. Feng S,
    4. Graham R,
    5. Gukasyan HJ.

    Eyes on Lipinski’s rule of five: a new “Rule of Thumb” for physicochemical design space of ophthalmic drugs. JJ Ocul Pharmacol Ther 2022; 38: 43–55.

    OpenUrl
32. 32.↵
    1. McGuire R,
    2. Roumen L

    1. Esch IJP de

    1. Vlieg J de

    1. G. Klomp JP

    1. A. Sanders MP

    , McGuire R, Roumen L, Esch IJP de, Vlieg J de, G. Klomp JP, et al. From the protein’s perspective: the benefits and challenges of protein structure-based pharmacophore modeling. MedChemComm 2012; 3: 28–38.

    OpenUrl